The assessment of individual and population bioequivalence

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We develop a statistical methodology for the assessment of individual bioequivalence when a crossover design is invoked. The location parameters for our model consist of population-averaged parameters for formulation, population-averaged parameters for nuisance effects (sequence, period, carryover, etc.), and subject-specific parameters for formulation. We do not impose any distributional assumptions other than the existence of first- and second-order moments. We derive unbiased estimators for all of the parameters in the model and construct subject-specific bioequivalence scores which exclude the effects of the nuisance parameters. We assess individual bioequivalence by constructing distribution-free tolerance intervals based on the sample of bioequivalence scores.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalJournal of Biopharmaceutical Statistics
Volume6
Issue number1
DOIs
StatePublished - Jan 1 1996

Fingerprint

Bioequivalence
Therapeutic Equivalency
Population parameter
Population
Tolerance Interval
Crossover Design
Formulation
Distribution-free
Location Parameter
Unbiased estimator
Nuisance Parameter
Cross-Over Studies
Moment
First-order
Methodology
Model

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{ebf3c377495b471999422255f8d79d30,
title = "The assessment of individual and population bioequivalence",
abstract = "We develop a statistical methodology for the assessment of individual bioequivalence when a crossover design is invoked. The location parameters for our model consist of population-averaged parameters for formulation, population-averaged parameters for nuisance effects (sequence, period, carryover, etc.), and subject-specific parameters for formulation. We do not impose any distributional assumptions other than the existence of first- and second-order moments. We derive unbiased estimators for all of the parameters in the model and construct subject-specific bioequivalence scores which exclude the effects of the nuisance parameters. We assess individual bioequivalence by constructing distribution-free tolerance intervals based on the sample of bioequivalence scores.",
author = "Vernon Chinchilli",
year = "1996",
month = "1",
day = "1",
doi = "10.1080/10543409608835118",
language = "English (US)",
volume = "6",
pages = "1--14",
journal = "Journal of Biopharmaceutical Statistics",
issn = "1054-3406",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

The assessment of individual and population bioequivalence. / Chinchilli, Vernon.

In: Journal of Biopharmaceutical Statistics, Vol. 6, No. 1, 01.01.1996, p. 1-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The assessment of individual and population bioequivalence

AU - Chinchilli, Vernon

PY - 1996/1/1

Y1 - 1996/1/1

N2 - We develop a statistical methodology for the assessment of individual bioequivalence when a crossover design is invoked. The location parameters for our model consist of population-averaged parameters for formulation, population-averaged parameters for nuisance effects (sequence, period, carryover, etc.), and subject-specific parameters for formulation. We do not impose any distributional assumptions other than the existence of first- and second-order moments. We derive unbiased estimators for all of the parameters in the model and construct subject-specific bioequivalence scores which exclude the effects of the nuisance parameters. We assess individual bioequivalence by constructing distribution-free tolerance intervals based on the sample of bioequivalence scores.

AB - We develop a statistical methodology for the assessment of individual bioequivalence when a crossover design is invoked. The location parameters for our model consist of population-averaged parameters for formulation, population-averaged parameters for nuisance effects (sequence, period, carryover, etc.), and subject-specific parameters for formulation. We do not impose any distributional assumptions other than the existence of first- and second-order moments. We derive unbiased estimators for all of the parameters in the model and construct subject-specific bioequivalence scores which exclude the effects of the nuisance parameters. We assess individual bioequivalence by constructing distribution-free tolerance intervals based on the sample of bioequivalence scores.

UR - http://www.scopus.com/inward/record.url?scp=0029965765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029965765&partnerID=8YFLogxK

U2 - 10.1080/10543409608835118

DO - 10.1080/10543409608835118

M3 - Article

C2 - 8838775

AN - SCOPUS:0029965765

VL - 6

SP - 1

EP - 14

JO - Journal of Biopharmaceutical Statistics

JF - Journal of Biopharmaceutical Statistics

SN - 1054-3406

IS - 1

ER -